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Abstract
Genetic association studies provide evidence for a substantial polygenic component to schizophrenia, although the
neurobiological mechanisms underlying the disorder remain largely undefined. Building on recent studies supporting a role
for developmentally regulated epigenetic variation in the molecular aetiology of schizophrenia, this study aimed to identify
epigenetic variation associated with both a diagnosis of schizophrenia and elevated polygenic risk burden for the disease
across multiple brain regions. Genome-wide DNA methylation was quantified in 262 post-mortem brain samples, represent-
ing tissue from four brain regions (prefrontal cortex, striatum, hippocampus and cerebellum) from 41 schizophrenia patients
and 47 controls. We identified multiple disease-associated and polygenic risk score-associated differentially methylated posi-
tions and regions, which are not enriched in genomic regions identified in genetic studies of schizophrenia and do not reflect
direct genetic effects on DNA methylation. Our study represents the first analysis of epigenetic variation associated with
schizophrenia across multiple brain regions and highlights the utility of polygenic risk scores for identifying molecular path-
ways associated with aetiological variation in complex disease.
Introduction
Schizophrenia is a severe neurodevelopmental disorder, charac-
terized by episodic psychosis and altered cognitive function (1)
that contributes significantly to the global burden of disease (2).
Twin and family studies have highlighted a notable heritable
component to schizophrenia (3), however the role of genetic
variation in the aetiology of the disorder is complex. Rare,
highly penetrant inherited and de novo mutations have been im-
plicated in some cases of schizophrenia (4–7), however, suscep-
tibility is predominantly attributed to the action of common
genetic variants of low penetrance. Recently, a large-scale ge-
nome-wide association study (GWAS) identified 108 indepen-
dent genomic loci exhibiting genome-wide significant
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association with schizophrenia, which provided convincing evi-
dence for a substantial polygenic component to aetiology within
signals falling below genome-wide levels of significance (8).
Despite these advances in understanding the genetic epidemi-
ology of schizophrenia, little is known about the mechanisms
by which schizophrenia risk variants mediate disease suscepti-
bility in the brain (9,10).
Improved understanding about the biology of the genome
has led to increased interest in the role of non-DNA sequence-
based variation in the aetiology of neurodevelopmental pheno-
types, including schizophrenia. Epigenetic processes have been
hypothesized to mediate associations between genetic risk bur-
den, environmental risk exposure and phenotype. Furthermore,
a growing number of studies provide evidence for the dysregu-
lation of epigenetic mechanisms in complex psychiatric disor-
ders (9,11–13). To date, such studies have primarily focused on
DNA methylation at CpG dinucleotides, as this is the best char-
acterized and most stable epigenetic modification. DNA methyl-
ation influences gene expression via physical disruption of
transcription factor binding and through the attraction of
methyl-binding proteins that initiate chromatin compaction
and gene silencing. Of note, previous studies characterizing
schizophrenia-associated methylomic variation have been lim-
ited by small sample number or the assessment of a single brain
region (14–19).
This study represents the first attempt to systematically ex-
amine the association of genome-wide methylomic variation
with schizophrenia and schizophrenia polygenic risk burden,
across multiple brain regions, using post-mortem tissue ob-
tained from two independent cohorts of schizophrenia patients
and controls.
Results
Overview of experimental strategy
We quantified genome-wide patterns of DNA methylation in
262 post-mortem samples derived from four brain regions dis-
sected from 88 individuals (41 schizophrenia and 47 non-
psychiatric controls) obtained from two independent brain
banks, using the Illumina Infinium HumanMethylation450
BeadChip (450K array) (Illumina Inc., San Diego, CA, USA) (see
Materials and Methods). In total, data from 76 prefrontal cortex
(PFC; n¼ 38 schizophrenia patients and 38 controls), 82 striatum
(STR; n¼ 37 schizophrenia patients and 45 controls), 27 hippo-
campus (HC; n¼ 14 schizophrenia patients and 13 controls) and
77 cerebellum (CER; n¼ 37 schizophrenia patients and 40 con-
trols) samples passed stringent quality control (QC) metrics and
were used for analysis (Table 1 and Supplementary Material,
Fig. S1). For post-mortem brain regions available from both
brain banks (PFC, STR and CER), a meta-analysis approach was
used to combine data from both sources. Our initial analyses fo-
cused on identifying differentially methylated positions (DMPs)
and differentially methylated regions (DMRs) associated with
disease status. Analyses were first performed independently for
each brain region, and we subsequently employed a multi-level
model to identify consistent DNA methylation markers of
schizophrenia present across multiple brain regions. We subse-
quently calculated a schizophrenia polygenic risk score (PRS) for
Caucasian samples (Supplementary Material, Table S1) to iden-
tify DMPs and DMRs associated with the polygenic risk burden.
A schematic overview of the study is given in Supplementary
Material, Fig. S2 with more detailed experimental procedures
described in the Material and Methods section.
Methylomic differences between schizophrenia cases
and controls – differentially methylated positions and
regions
No global differences in DNA methylation—estimated by aver-
aging across all probes on the array included in our analysis—
were identified between schizophrenia patients and controls in
any of the four brain regions (PFC: schizophrenia (SZ)¼ 48.43%,
controls (CTR)¼ 48.57%, P¼ 0.51; STR: SZ¼ 49.20%, CTR¼ 49.16%,
P¼ 0.12; HC: SZ¼ 48.44%, CTR¼ 48.38%, P¼ 5.31E-02; CER:
SZ¼ 47.25%, CTR¼ 47.27%, P¼ 0.89). Furthermore, the estimated
‘DNA methylation age’ for each sample – calculated using an
epigenetic clock based on DNA methylation values (20,21) – was
strongly correlated with actual chronological age in each brain
region (PFC: q¼ 0.94, P< 2.20E-16; STR: q¼ 0.93, P< 2.20E-16; HC:
q¼ 0.94, P¼ 1.30E-13; CER: q¼ 0.86, P¼ 2.20E-16) (Supplementary
Material, Fig. S3), with no evidence for accelerated ‘epigenetic
aging’ in affected individuals (PFC: P¼ 0.16, STR: P¼ 0.73, HC:
P¼ 0.73, CER: P¼ 0.30). Taken together, these data indicate that
schizophrenia is not associated with any systemic methylomic
differences across the probes included on the Illumina 450K ar-
ray in the brain regions tested in this study.
In contrast, we find significant evidence for schizophrenia-
associated variation at specific loci across the genome in each
brain region. Our first analyses focused on identifying DNA
methylation differences between schizophrenia cases and non-
psychiatric controls. The fifty top-ranked schizophrenia-associ-
ated DMPs in each brain region are listed in Supplementary
Materials, Tables S2–S5, Figs S4–S7, with 12 DMPs passing a
highly stringent significance threshold (P< 1.66E-07, see
Materials & Methods) (Table 2, Fig. 1, Supplementary Material,
Fig. S8). Results for all probes included in the final QC’d dataset
can be downloaded from http://epigenetics.essex.ac.uk/schizo
brain/. Although the specific list of top-ranked DMPs identified
in each tissue is relatively distinct, many DMPs are character-
ized by consistent effects across brain regions (Supplementary
Materials, Figs S4–S7), and for DMPs identified in each of the
four individual brain regions, schizophrenia-associated DNA
methylation differences are significantly positively correlated
with those at the same probes in the other three brain regions
(correlations for: PFC DMPs¼ 0.43 (STR), 0.31 (HC), 0.61 (CER);
STR DMPs¼ 0.77 (PFC), 0.65 (HC), 0.74 (CER); HC DMPs¼ 0.63
(PFC), 0.74 (HC), 0.54 (CER); and CER DMPs¼ 0.64 (PFC), 0.36 (STR),
0.46 (HC)) (Supplementary Material, Fig. S9).
Quantile-quantile (Q-Q) plots for the P-values of the analyses
in each tissue are shown in Supplementary Material, Fig. S10A–
D highlighting some evidence of P-value inflation (PFC k¼ 1.18,
STR k¼ 1.02, HC k¼ 1.13, CER k¼ 1.23) in several of the brain re-
gions; such inflation is not unusual in epigenome-wide associa-
tion study (EWAS) analyses and standard genomic control
methods – widely used in GWAS – are not suitable for EWAS
data (22). Because it is likely that unmeasured factors beyond
the variables included in our analysis model (i.e. age, sex, and
estimated neuronal proportion) confound our case-control anal-
ysis of methylomic variation associated with schizophrenia, we
therefore investigated the impact of additional surrogate vari-
ables capturing variation in DNA methylation on the associa-
tion statistics for schizophrenia-associated DMPs. We
compared the regression coefficients from our initial analysis
model to sequential models iteratively including up to 10 princi-
pal components (PCs) derived from the DNA methylation data,
observing a strong positive correlation for schizophrenia-
associated DNA methylation differences between analyses
(Supplementary Materials, Figs S11–S14). This sensitivity
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analysis implies that although additional confounders poten-
tially exist in our dataset, the identified schizophrenia-
associated DMPs are relatively robust to the major PCs associ-
ated with methylomic variance.
We next used comb-p (23) (see Materials and Methods) to
identify spatially correlated regions of differential DNA methyl-
ation significantly associated with schizophrenia (Sidak-
corrected P< 0.05, number of consecutive probes 2) in each of
the four brain regions (PFC: 13 DMRs spanning an average of 7
probes and 279bp; STR: 2 DMRs spanning an average of 8 probes
and 328bp; HC: 1 DMRs spanning an average of 7 probes and
260bp; CER: 10 DMRs spanning an average of 5 probes and
246bp) (Fig. 2 and Table 3). Many DMRs are again characterized
by consistent schizophrenia-associated differences in DNA
methylation across multiple brain regions (Fig. 2). Of note, a
DMR spanning four probes within the RPH3AL gene on chromo-
some 17, which encodes a protein that plays a direct regulatory
role in calcium-ion-dependent exocytosis, is consistently hypo-
methylated in schizophrenia patients across all four brain re-
gions (PFC: median DNA methylation difference¼8.03%,
median P¼ 8.27E-04; STR: median DNA methylation differ-
ence¼5.32%, median P¼ 7.14E-03; HC: median DNA methyla-
tion difference¼7.84%, median P¼ 1.78E-02; CER: median DNA
methylation difference¼10.24, median P¼ 3.86E-03) (Fig. 2
and Supplementary Materials, Figs S15 and S16). We subse-
quently confirmed schizophrenia-associated hypomethylation
across the same region using Bumphunter (24)—an alternative
DMR analysis approach – in the PFC (P¼ 4.85E-05), STR (P¼ 2.
00E-04) and CER (P¼ 6.01E-06). To validate the differences iden-
tified across this DMR using the Illumina 450K array we em-
ployed bisulfite-pyrosequencing to quantify DNA methylation
across an amplicon spanning three CpG sites (including
cg11940040 and two adjacent CpG sites not on the 450K array) in
the PFC (n¼ 35 schizophrenia and 36 controls) and STR (n¼ 36
schizophrenia and 41 controls) samples. All three sites were sig-
nificantly hypomethylated in schizophrenic patients compared
to controls in both brain regions (Supplementary Materials,
Table S6, Figs S15 and S16), with DNA methylation differences
reflecting those identified using the 450K array (PFC: average
DNA methylation difference¼8.68%, P¼ 1.72E-03; STR: aver-
age DNA methylation difference¼5.33%, P¼ 1.41E-02).
Consistent methylomic markers of schizophrenia across
brain regions
We next employed a multi-level model to further explore con-
sistent schizophrenia-associated differences across multiple
brain regions (see Material and Methods). As reported in previ-
ous analyses of epigenetic variation in the human brain (25–27),
our data show that at a global level the patterns of DNA methyl-
ation in the CER are very distinct to the other three brain regions
included in this study (Supplementary Material, Fig. S17); for
this reason we excluded the CER from our multi-region model
and focused on identifying consistent signals across the PFC,
STR and HC. Of note, there is inflation in the distribution of P-
values in the multi-region case-control analysis (k¼ 1.43,
Supplementary Material, Fig. S9E); although our model is de-
signed to control for the non-independence of brain regions
from the same individual, it is possible that combining datasets
has resulted in some residual inflation. Compared to other pub-
lished EWAS analyses, however, this inflation is relatively
Table 1. Overview of samples included in the schizophrenia case versus control analysis. LNDBB¼MRC London Neurodegenerative Diseases
Brain Bank, DBCBB¼Douglas-Bell Canada Brain Bank.
N Sex (male:female) Age at death Brain weight (g) pH
LNDBB Prefrontal cortex schizophrenia 20 11:9 62.056 15.87 1232.94 6 129.22 6.64 6 0.28
controls 23 17:6 62.046 18.74 1368.48 6 185.22 6.49 6 0.33
total 43 28:15 62.05 6 17.26 1310.88 6 175.52 6.56 6 0.31
P – – 1.00 0.01 0.13
Striatum schizophrenia 21 11:10 61.76 6 16.61 1227.44 6 123.68 6.60 6 0.30
controls 28 20:8 63.436 18.16 1360.52 6 184.59 6.46 6 0.33
total 49 31:18 62.71 6 17.36 1302.10 6 172.37 6.53 6 0.32
P – – 0.74 0.01 0.17
Hippocampus schizophrenia 14 10:4 60.716 15.93 1271.25 6 139.22 6.63 6 0.28
controls 13 11:2 61.926 17.80 1415.27 6 173.82 6.48 6 0.41
total 27 21:6 61.306 16.54 1340.13 6 169.81 6.56 6 0.34
P – – 0.85 0.04 0.31
Cerebellum schizophrenia 21 11:10 61.76 6 16.61 1227.44 6 123.68 6.60 6 0.30
controls 23 17:6 61.396 19.25 1361.30 6 185.03 6.46 6 0.33
total 44 28:16 61.57 6 17.83 1232.41 6 172.79 6.60 6 0.32
P – – 0.95 0.01 0.15
DBCBB Prefrontal cortex schizophrenia 18 15:3 45.506 16.61 1431.78 6 188.16 6.23 6 0.22
controls 15 13:2 42.276 14.80 1462.96 6 175.17 6.12 6 0.32
total 33 28:5 44.036 15.65 1447.37 6 179.32 6.18 6 0.27
P – – 0.56 0.64 0.27
Striatum schizophrenia 16 13:3 46.256 17.10 1410.90 6 193.35 6.21 6 0.22
controls 17 14:3 45.656 16.82 1438.02 6 180.91 6.09 6 0.31
total 33 27:6 45.946 16.69 1426.27 6 183.61 6.15 6 0.27
P – – 0.92 0.70 0.23
Cerebellum schizophrenia 16 14:2 44.566 15.84 1404.62 6 161.90 6.25 6 0.22
controls 17 14:3 45.656 16.82 1438.02 6 180.91 6.09 6 0.31
total 33 28:5 45.126 16.10 1422.94 6 170.58 6.17 6 0.28
P – – 0.85 0.59 0.10
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modest and we do not identify an excessively large number of
DMPs passing our stringent family-wise significance threshold.
Supplementary Materials, Table S7, Fig. S18 lists the 50 top-
ranked cross-region DMPs, with significant cross-region DMRs
listed in Supplementary Materials, Table S8, Fig. S19; in total we
identified 22 DMRs spanning an average of 6 probes and 317bp.
The multi-region model DMPs provide further support for sev-
eral loci identified in our previous study of schizophrenia pre-
frontal cortex (17) including GSDMD (cg26173173: P¼ 4.28E-05),
RASA3 (cg24803255: P¼ 1.51E-04), PPFIA1 (cg08171022: P¼ 1.19E-
02) and MYT1L (cg00236305: P¼ 4.62E-04) (Supplementary
Material, Table S9), suggesting that DNA methylation differ-
ences at these loci are consistently-associated with schizophre-
nia across the three regions. Of note, the top-ranked cross-
region DMRs include a highly-significant signal spanning 11
CpG sites (Sidak-corrected P¼ 8.90E-11) annotated to WNT5A
(28), in addition to regions annotated several loci identified in
the analyses of the different brain regions such as GBP4 (Sidak-
corrected P¼ 0.01), PRDM9 (Sidak-corrected P¼ 0.04) and RPH3AL
(Sidak-corrected P¼ 1.23E-05).
Methylomic variation associated with schizophrenia
polygenic risk score (PRS)
A recent large-scale GWAS of schizophrenia identified 128 inde-
pendent associations spanning 108 genomic regions in a meta-
analysis of over 80,000 samples (8). 5006, 5058, 5066 and 4951
Illumina 450K array probes included in our PFC, STR, HC and
CER analyses, respectively, are located within these broad geno-
mic regions. Although a number of probes within these regions
were nominally associated with schizophrenia (see
Supplementary Material, Table S10 for all DMPs with P< 1.00E-
03), we found no overall enrichment of DMPs in any of the anal-
yses performed (Fisher’s exact test: PFC P¼ 0.20, STR P¼ 0.27, HC
P¼ 0.59, CER P¼ 0.55, multi-region model P¼0.04) at a
Bonferroni corrected P-value for the number of tests performed
(P< 1.25E-02).
Beyond the specific genome-wide significant loci identified
in GWAS, an individual’s accumulated genetic burden can be
quantified to define an overall PRS – i.e. the sum of trait-
associated alleles across many genetic loci, weighted by effect
sizes estimated by GWAS analyses (8,29). We next explored if an
increased burden of polygenic variants associated with schizo-
phrenia was itself associated with variation in DNA methylation
in the brain. Each sample was genotyped and SNP data was im-
puted using the latest data release from the 1,000 Genomes
project, and a PRS for each sample was generated using data
from the recent schizophrenia GWAS (8) (see Materials and
Methods). None of the samples used in this study were included
in the PGC GWAS analysis of schizophrenia, and thus did not
contribute to defining the variants included in the PRS. To avoid
population stratification effects, ethnicity was determined us-
ing data from HapMap Phase 3 (see Materials and Methods) and
non-Caucasian samples (n¼ 10) were excluded from subsequent
PRS-based analyses. Despite the relatively small sample size
(see Supplementary Material, Table S1 for an overview of sam-
ples), schizophrenia patients (n¼ 34) were characterized by a
significantly higher PRS than controls (n¼ 40) (P¼ 4.42E-03) (Fig.
3A). For Caucasian samples, we repeated our case-control study
with and without the inclusion of PRS as a covariate. For the
top-ranked DMPs associated with schizophrenia (presented
above), there was a highly-significant correlation of
both schizophrenia-associated DNA methylation difference andT
ab
le
2.
T
o
p
-r
an
ke
d
sc
h
iz
o
p
h
re
n
ia
-a
ss
o
ci
at
ed
d
if
fe
re
n
ti
al
ly
m
et
h
yl
at
ed
p
o
si
ti
o
n
s
(D
M
Ps
).
Sh
o
w
n
ar
e
D
M
Ps
as
so
ci
at
ed
w
it
h
sc
h
iz
o
p
h
re
n
ia
at
a
h
ig
h
ly
st
ri
n
ge
n
t
si
gn
ifi
ca
n
ce
th
re
sh
o
ld
(P
<
1.
66
E-
07
)
d
er
iv
ed
u
si
n
g
p
er
m
u
ta
ti
o
n
s
to
es
ti
m
at
e
th
e
n
o
m
in
al
P-
va
lu
e
fo
r
5%
fa
m
il
y-
w
is
e
er
ro
r.
T
o
p
-r
an
ke
d
sc
h
iz
o
p
h
re
n
ia
-a
ss
o
ci
at
ed
D
M
Ps
fo
r
ea
ch
o
f
th
e
fo
u
r
br
ai
n
re
gi
o
n
s
p
ro
fi
le
d
ar
e
p
re
se
n
te
d
in
Su
p
p
le
m
en
ta
ry
M
at
er
ia
ls
,
T
ab
le
s
S2
–S
5.
Il
lu
m
in
a
an
d
G
en
o
m
ic
R
eg
io
n
s
En
ri
ch
m
en
t
o
f
A
n
n
o
ta
ti
o
n
T
o
o
l
(G
R
EA
T
)
(3
8)
an
n
o
ta
ti
o
n
is
li
st
ed
fo
r
ea
ch
D
M
P.
LN
D
B
B
¼
Lo
n
d
o
n
N
eu
ro
d
eg
en
er
at
iv
e
D
is
o
rd
er
s
B
ra
in
B
an
k;
D
B
C
B
B
¼
D
o
u
gl
as
-B
el
lC
an
ad
a
B
ra
in
B
an
k.
N
o
te
h
ip
p
o
ca
m
p
u
s
ti
ss
u
e
w
as
n
o
t
av
ai
la
bl
e
fr
o
m
th
e
D
B
C
B
B
.
Pr
o
be
ID
G
en
o
m
ic
p
o
si
ti
o
n
(h
g1
9)
Il
lu
m
in
a
ge
n
e
an
n
o
ta
ti
o
n
G
en
ic
re
gi
o
n
G
R
EA
T
an
n
o
ta
ti
o
n
(3
8)
B
ra
in
re
gi
o
n
D
N
A
m
et
h
yl
at
io
n
d
if
fe
re
n
ce
(%
)
P
D
N
A
m
et
h
yl
at
io
n
d
if
fe
re
n
ce
(%
)L
N
D
B
B
P-
va
lu
e
LN
D
B
B
D
N
A
m
et
h
yl
at
io
n
d
if
fe
re
n
ce
(%
)D
B
C
B
B
P-
va
lu
e
D
B
C
B
B
cg
08
74
30
50
ch
r1
1:
11
31
13
93
6
N
C
A
M
1
B
o
d
y
T
T
C
12
;N
C
A
M
1
Pr
ef
ro
n
ta
lc
o
rt
ex
3
.8
0
1.
84
E-
08
1
.8
0
0.
15
4
.6
3
8.
39
E-
09
cg
14
60
94
48
ch
r2
1:
34
89
68
82
G
A
R
T
B
o
d
y;
3’
U
T
R
D
N
A
JC
28
;G
A
R
T
C
er
eb
el
lu
m
2.
29
2.
48
E-
08
1.
37
0.
02
3.
11
3.
60
E-
08
cg
08
10
31
44
ch
r5
:1
50
02
89
86
SY
N
PO
B
o
d
y
M
Y
O
Z
3;
SY
N
PO
St
ri
at
u
m
3
.1
7
3.
64
E-
08
0.
08
0.
94
4
.4
3
6.
61
E-
11
cg
03
84
74
32
ch
r7
:4
33
91
52
4
H
EC
W
1
B
o
d
y
ST
K
17
A
;H
EC
W
1
St
ri
at
u
m
2.
71
5.
23
E-
08
1.
55
0.
04
3.
69
4.
76
E-
08
cg
22
18
20
16
ch
r1
5:
57
99
88
94
G
R
IN
L1
A
;G
C
O
M
1
T
SS
20
0;
B
o
d
y
PO
LR
2M
St
ri
at
u
m
0
.5
1
5.
67
E-
08
0
.2
7
0.
14
0
.5
9
5.
41
E-
08
cg
01
75
71
60
ch
r1
2:
96
58
89
51
EL
K
3
5’
U
T
R
EL
K
3
C
er
eb
el
lu
m
0.
57
5.
74
E-
08
0.
58
5.
13
E-
04
0.
56
3.
04
e-
05
cg
25
36
16
51
ch
r2
0:
29
84
74
02
D
EF
B1
15
B
o
d
y
D
EF
B1
15
;D
EF
B1
16
St
ri
at
u
m
4.
43
6.
52
E-
08
2.
27
0.
10
5.
63
3.
67
E-
08
cg
22
22
13
20
ch
r1
:8
96
64
34
0
G
BP
4
B
o
d
y
G
BP
4
St
ri
at
u
m
6.
93
7.
88
E-
08
2.
39
0.
23
10
.2
4
1.
58
E-
09
cg
07
75
12
66
ch
r1
6:
67
51
53
23
A
T
P6
V
0D
1
T
SS
15
00
A
T
P6
V
0D
1
H
ip
p
o
ca
m
p
u
s
1
.3
5
1.
27
E-
07
1
.3
5
1.
27
E-
07
–
–
cg
09
75
74
30
ch
r1
3:
28
39
71
22
-
–
PD
X
1;
G
SX
1
C
er
eb
el
lu
m
3
.1
3
1.
37
E-
07
2
.3
8
0.
02
3
.5
4
1.
65
E-
06
cg
05
68
64
45
ch
r7
:1
27
63
63
96
C
7o
rf
54
;S
N
D
1
T
SS
15
00
;B
o
d
y
LR
R
C
4;
SN
D
1
Pr
ef
ro
n
ta
lc
o
rt
ex
3
.6
5
1.
63
E-
07
2
.0
4
0.
07
4
.6
7
1.
57
E-
07
cg
20
75
17
95
ch
r1
9:
58
28
10
19
Z
N
F5
86
T
SS
20
0
Z
N
F5
86
C
er
eb
el
lu
m
0.
57
1.
64
E-
07
0.
42
1.
17
E-
06
0.
13
0.
03
4 | Human Molecular Genetics, 2016, Vol. 00, No. 00
 at U
niversity of Essex on January 12, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Figure 2. Differentially methylated regions (DMRs) associated with schizophrenia. Shown in chromosomal order are DMRs (Sidak-corrected P<0.05, number of
probes2) associated with schizophrenia identified in any of the four tissues. Effect sizes for individual probes within each DMR are also shown for the other three
brain regions (blue¼hypomethylation, red¼hypermethylation). Further details for individual DMRs are provided in Table 3.
Figure 1. Forest plots showing the top-ranked schizophrenia-associated differentially methylated positions (DMPs). Shown are data for 12 DMPs associated with
schizophrenia at a highly stringent significance threshold (P<1.66E-07) derived using permutations to estimate the nominal P-value for 5% family-wise error.
Additional information on these DMPs is given in Table 2. Colour depicts a brain region in which the schizophrenia-association was identified: prefrontal cortex¼blue,
striatum¼ green, hippocampus¼ red, and cerebellum¼yellow.
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P-value across all four brain regions (correlations ranging
from 0.80 to 1.00 for all comparisons, except for the HC (0.56–1.
00)), indicating that polygenic risk burden is not impacting greatly
on the schizophrenia-associated differences identified.
We next employed a linear model, controlling for age, sex,
and neuronal estimates (except in the CER, as described in
Materials and Methods) to identify methylomic variation associ-
ated with the schizophrenia PRS. Q-Q plots for the P-values of
the analyses in each tissue are shown in Supplementary
Material, Fig. S20, again providing evidence of some P-value in-
flation (PFC k¼ 0.96, STR k¼ 1.10, HC k¼ 1.17, CER k¼ 1.26) in
some brain regions. The 15 PRS-associated DMPs passing our
stringent significance threshold listed in Table 4 and the fifty
top-ranked PRS-associated DMPs in each brain region presented
in Supplementary Materials, Figs S21–S24, Tables S11–S14.
Results for all probes included in the analysis of PRS can be
downloaded from http://epigenetics.essex.ac.uk/schizobrain/.
The top-ranked PRS-associated DMP is cg20640266 (annotated
to the zinc-finger gene ZNF618), at which an increased polygenic
burden was associated with elevated DNA methylation in the
CER (P¼ 6.50E-07) (Fig. 3B). Although the specific top-ranked
PRS-associated loci in each tissue are distinct, effect sizes at
PRS-associated DMPs are significantly correlated across brain
regions (Supplementary Materials, Table S15, Fig. S25), with the
exception of the HC where the low number of samples (n¼ 23)
means we are probably underpowered to detect robust effects.
Furthermore, although there is no direct overlap between the
top-ranked schizophrenia-associated and PRS-associated DMPs,
the effect sizes at the top-ranked PRS-associated probes are sig-
nificantly correlated with those at the same sites in the case-
control analysis, and vice versa, across all brain regions
(Supplementary Materials, Figs S26–S29). We used to identify
spatially correlated regions of differential DNA methylation sig-
nificantly associated with polygenic burden for schizophrenia
(Sidak-corrected P< 0.05, number of consecutive probes 2).
PRS-associated DMRs in each of the four brain regions are listed
in Table 5 and Fig. 4 (PFC: 6 DMRs spanning an average of 6
probes and 291bp; STR: 4 DMRs spanning an average of 5 probes
and 237bp; CER: 10 DMRs spanning an average of 6 probes and
340bp; no DMRs were identified in the HC).
We next employed a multi-level model to identify consistent
PRS-associated DMPs (Supplementary Material, Fig. S30, Table
S16) and DMRs (Supplementary Materials, Fig. S31, Table S17
across PFC, STR and HC. Of note, the top-ranked PRS-associated
DMP (cg04910228), at which PRS is negatively correlated with
DNA methylation (estimate¼0.38%, P¼ 6.50E-07), is located
within the TSNAX-DISC1 locus on chromosome 1 (Fig. 3C). A bal-
anced translocation involving this gene that segregates with
several major psychiatric disorders including schizophrenia has
been intensively studied in a Scottish pedigree (5), although the
involvement of this locus in the aetiology of the disorder re-
mains controversial and common genetic variation in this re-
gion was not identified in recent GWAS analyses (30,31). Our
data suggest that an increased polygenic burden for schizophre-
nia may impact upon regulatory variation of the DISC1 locus in
the brain.
Polygenic risk score-associated methylomic variation
does not reflect direct genetic effects on DNA
methylation
Although one of the top-ranked PRS-associated DMPs was lo-
cated within a GWAS-nominated genomic region—cg01682070T
ab
le
3.
C
o
n
ti
n
u
ed
R
eg
io
n
G
en
e(
s)
Pr
o
be
s
N
p
ro
be
s
Pr
ef
ro
n
ta
lc
o
rt
ex
St
ri
at
u
m
H
ip
p
o
ca
m
p
u
s
C
er
eb
el
lu
m
M
ed
ia
n
P
 Si
d
 ak
P
M
ed
ia
n
P
 Si
d
 ak
P
M
ed
ia
n
P
 Si
d
 ak
P
M
ed
ia
n
P
 Si
d
 ak
P
ch
r1
1:
34
46
02
98
-3
44
60
55
8
C
A
T
cg
20
73
11
36
;c
g0
60
27
90
6;
cg
07
76
82
01
;
cg
03
72
00
43
;c
g0
21
09
65
2;
cg
06
90
84
74
;
cg
01
84
77
19
7
0.
36
3.
61
E-
02
1.
00
E-
02
9.
44
E-
04
0.
21
ch
r1
2:
12
51
45
44
6-
12
51
45
64
2
N
C
O
R
2;
SC
A
R
B1
cg
12
07
76
64
;c
g2
76
45
49
8;
cg
19
88
85
09
3
2.
00
E-
03
2.
20
E-
02
0.
56
0.
59
0.
18
ch
r1
2:
13
14
52
23
8-
13
14
52
29
8
SF
SW
A
P;
G
PR
13
3
cg
24
33
63
38
;c
g0
37
76
87
8;
cg
23
61
78
48
3
0.
80
0.
23
0.
59
1.
20
E-
04
2.
50
E-
03
ch
r1
3:
11
42
02
68
3-
11
42
02
86
2
T
FD
P1
;T
M
C
O
3
cg
16
56
77
23
;c
g2
41
21
06
9;
cg
11
31
23
53
3
6.
38
E-
04
1.
94
E-
02
0.
12
0.
74
9.
18
E-
03
ch
r1
6:
28
92
51
8-
28
92
91
3
PR
SS
30
P;
T
M
PR
SS
8
cg
07
64
57
61
;c
g0
04
91
18
0;
cg
01
00
68
02
;
cg
27
13
72
58
;c
g1
04
48
22
7;
cg
10
18
64
56
6
7.
18
E-
03
5.
65
E-
03
3.
91
E-
02
0.
12
4.
27
E-
03
1.
62
E-
04
ch
r1
7:
15
44
10
-1
54
67
2
D
O
C
2B
;R
PH
3A
L
cg
08
77
08
70
;c
g1
19
40
04
0;
cg
10
44
06
39
;
cg
23
24
69
11
4
8.
27
E-
04
1.
02
E-
04
7.
14
E-
03
1.
78
E-
02
3.
86
E-
03
3.
44
E-
02
ch
r1
9:
19
63
99
70
-1
96
40
07
6
Y
JE
FN
3
cg
11
24
46
72
;c
g2
00
98
71
0
2
3.
00
E-
04
4.
49
E-
02
0.
43
0.
50
0.
54
ch
r1
9:
57
74
21
12
-5
77
42
44
5
A
U
R
K
C
cg
25
80
28
88
;c
g1
95
68
00
3;
cg
18
64
42
86
;
cg
26
33
21
14
;c
g1
96
03
90
3;
cg
23
37
14
13
;
cg
06
64
38
49
;c
g2
54
32
23
2;
cg
22
71
17
41
9
0.
23
1.
34
E-
02
2.
64
E-
03
0.
86
0.
27
ch
r2
1:
46
89
80
48
-4
68
98
13
8
C
O
L1
8A
1;
SL
C
19
A
1
cg
03
20
81
98
;c
g2
03
83
94
8
2
1.
30
E-
04
2.
31
E-
02
0.
68
0.
49
0.
14
7Human Molecular Genetics, 2016, Vol. 00, No. 00 |
 at U
niversity of Essex on January 12, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
T
ab
le
4.
T
o
p
-r
an
ke
d
d
if
fe
re
n
ti
al
ly
m
et
h
yl
at
ed
p
o
si
ti
o
n
s
(D
M
Ps
)
as
so
ci
at
ed
w
it
h
sc
h
iz
o
p
h
re
n
ia
p
o
ly
ge
n
ic
sc
o
re
(P
R
S)
.
Sh
o
w
n
ar
e
D
M
Ps
as
so
ci
at
ed
w
it
h
th
e
sc
h
iz
o
p
h
re
n
ia
PR
S
at
a
h
ig
h
ly
st
ri
n
ge
n
t
si
gn
ifi
ca
n
ce
th
re
sh
o
ld
(P
<
1.
66
E-
07
)
d
er
iv
ed
u
si
n
g
p
er
m
u
ta
ti
o
n
s
to
es
ti
m
at
e
th
e
n
o
m
in
al
P-
va
lu
e
fo
r
5%
fa
m
il
y-
w
is
e
er
ro
r.
T
o
p
-r
an
ke
d
PR
S-
as
so
ci
at
ed
D
M
Ps
fo
r
ea
ch
o
f
th
e
fo
u
r
br
ai
n
re
gi
o
n
s
p
ro
-
fi
le
d
ar
e
p
re
se
n
te
d
in
Su
p
p
le
m
en
ta
ry
M
at
er
ia
ls
,T
ab
le
s
S1
2–
S1
5.
T
h
e
m
et
h
yl
at
io
n
d
if
fe
re
n
ce
is
m
ea
su
re
d
p
er
PR
S
u
n
it
.I
ll
u
m
in
a
an
d
G
en
o
m
ic
R
eg
io
n
s
En
ri
ch
m
en
t
o
f
A
n
n
o
ta
ti
o
n
T
o
o
l
(G
R
EA
T
)
(3
8)
an
n
o
ta
ti
o
n
is
li
st
ed
fo
r
ea
ch
D
M
P.
LN
D
B
B
¼
Lo
n
d
o
n
N
eu
ro
d
eg
en
er
at
iv
e
D
is
o
rd
er
s
B
ra
in
B
an
k;
D
B
C
B
B
¼
D
o
u
gl
as
-B
el
lC
an
ad
a
B
ra
in
B
an
k.
Pr
o
be
ID
G
en
o
m
ic
p
o
si
ti
o
n
(h
g1
9)
Il
lu
m
in
a
ge
n
e
an
n
o
ta
ti
o
n
G
en
e
re
gi
o
n
G
R
EA
T
an
n
o
ta
ti
o
n
(3
8)
B
ra
in
re
gi
o
n
D
N
A
m
et
h
yl
at
io
n
ch
an
ge
(%
)
P
D
N
A
m
et
h
yl
at
io
n
ch
an
ge
(%
)L
N
D
B
B
P-
va
lu
e
LN
D
B
B
D
N
A
m
et
h
yl
at
io
n
ch
an
ge
(%
)D
B
C
B
B
P-
va
lu
e
D
B
C
B
B
cg
18
84
70
09
ch
r2
:7
01
75
82
6
–
–
A
SP
R
V
1;
M
X
D
1
Pr
ef
ro
n
ta
lc
o
rt
ex
0
.5
1
8.
98
E-
08
0
.5
0
7.
14
E-
07
0
.6
6
0.
03
cg
26
89
34
45
ch
r1
5:
85
92
41
87
A
K
A
P1
3
5’
U
T
R
A
K
A
P1
3
St
ri
at
u
m
0.
15
6.
73
E-
08
0.
16
6.
80
E-
08
0.
03
0.
21
cg
12
59
52
81
ch
r1
5:
93
63
31
72
R
G
M
A
T
SS
15
00
R
G
M
A
St
ri
at
u
m
0.
68
6.
85
E-
08
0.
82
5.
36
E-
10
0.
13
0.
07
cg
20
64
02
66
ch
r9
:1
16
81
17
89
Z
N
F6
18
B
o
d
y
A
M
BP
;Z
N
F6
18
C
er
eb
el
lu
m
0.
60
1.
62
E-
09
0.
74
2.
06
E-
06
0.
32
0.
02
cg
27
15
05
52
ch
r7
:4
80
26
85
6
SU
N
C
1
3’
U
T
R
H
U
S1
;S
U
N
3
C
er
eb
el
lu
m
0.
34
1.
30
E-
08
0.
36
6.
44
E-
09
0.
09
0.
68
cg
05
20
97
68
ch
r2
:1
64
57
36
65
FI
G
N
B
o
d
y
K
C
N
H
7;
FI
G
N
C
er
eb
el
lu
m
0.
70
1.
55
E-
08
0.
70
1.
31
E-
07
0.
70
0.
04
cg
07
79
38
08
ch
r1
2:
12
20
19
00
6
K
D
M
2B
T
SS
20
0;
T
SS
15
00
K
D
M
2B
C
er
eb
el
lu
m
0
.1
9
1.
66
E-
08
0
.2
1
2.
94
E-
04
0
.1
7
1.
28
E-
05
cg
10
21
87
77
ch
r3
:1
33
18
02
61
BF
SP
2
B
o
d
y
C
D
V
3;
BF
SP
2
C
er
eb
el
lu
m
0.
67
3.
86
E-
08
0.
65
4.
24
E-
07
0.
86
0.
03
cg
01
68
20
70
ch
r1
6:
29
99
67
74
T
A
O
K
2
B
o
d
y
H
IR
IP
3;
T
A
O
K
2
C
er
eb
el
lu
m
0.
32
4.
20
E-
08
0.
37
1.
21
E-
08
0.
11
0.
38
cg
11
78
65
58
ch
r1
7:
22
66
58
9
SG
SM
2
B
o
d
y
SG
SM
2;
M
N
T
C
er
eb
el
lu
m
0.
69
4.
35
E-
08
0.
84
1.
23
E-
06
0.
52
4.
73
E-
03
cg
26
05
30
83
ch
r1
1:
14
99
57
70
–
–
C
A
LC
A
C
er
eb
el
lu
m
0
.1
5
4.
41
E-
08
0
.1
5
2.
53
E-
06
0
.1
4
4.
95
E-
03
cg
01
02
28
40
ch
r1
4:
71
25
02
64
M
A
P3
K
9
B
o
d
y
M
A
P3
K
9;
T
T
C
9
C
er
eb
el
lu
m
0.
63
7.
86
E-
08
0.
66
7.
10
E-
07
0.
53
0.
04
cg
08
47
85
39
ch
r1
5:
68
64
03
39
IT
G
A
11
B
o
d
y
FE
M
1B
;I
T
G
A
11
C
er
eb
el
lu
m
0.
69
1.
06
E-
07
0.
80
3.
06
E-
07
0.
45
0.
06
cg
23
78
83
34
ch
r2
:1
37
18
11
76
–
–
T
H
SD
7B
;C
X
C
R
4
C
er
eb
el
lu
m
0
.1
3
1.
15
E-
07
0
.1
5
1.
45
E-
05
0
.1
1
1.
56
E-
03
cg
16
90
45
20
ch
r2
:2
30
59
09
62
–
–
D
N
ER
;T
R
IP
12
C
er
eb
el
lu
m
0.
26
1.
25
E-
07
0.
27
2.
06
E-
06
0.
22
0.
02
Fi
gu
re
3.
In
cr
ea
se
d
p
o
ly
ge
n
ic
bu
rd
en
fo
r
sc
h
iz
o
p
h
re
n
ia
is
as
so
ci
at
ed
w
it
h
al
te
re
d
D
N
A
m
et
h
yl
at
io
n
.(
A
)S
ch
iz
o
p
h
re
n
ia
sa
m
p
le
s
in
cl
u
d
ed
in
o
u
r
st
u
d
y
sc
o
re
d
si
gn
ifi
ca
n
tl
y
h
ig
h
er
o
n
a
p
o
ly
ge
n
ic
ri
sk
sc
o
re
d
er
iv
ed
fr
o
m
a
re
ce
n
t
la
rg
e
co
ll
ab
o
ra
ti
ve
G
W
A
S
o
f
sc
h
iz
o
p
h
re
n
ia
.
(B
)
T
h
e
to
p
-r
an
ke
d
PR
S-
as
so
ci
at
ed
D
M
P
w
as
cg
20
64
02
66
(a
n
n
o
ta
te
d
to
Z
N
F6
18
)
in
th
e
ce
re
be
ll
u
m
.
(C
)
T
h
e
to
p
-r
an
ke
d
m
u
lt
i-
re
gi
o
n
PR
S-
as
so
ci
at
ed
D
M
P
w
as
cg
04
91
02
28
(a
n
n
o
ta
te
d
to
th
e
T
SN
A
X
-D
IS
C
1
lo
cu
s)
.
8 | Human Molecular Genetics, 2016, Vol. 00, No. 00
 at U
niversity of Essex on January 12, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
T
ab
le
5.
D
if
fe
re
n
ti
al
ly
m
et
h
yl
at
ed
re
gi
o
n
s
(D
M
R
s)
si
gn
ifi
ca
n
tl
y
as
so
ci
at
ed
w
it
h
p
o
ly
ge
n
ic
sc
o
re
(P
R
S)
fo
r
sc
h
iz
o
p
h
re
n
ia
.S
h
o
w
n
in
ch
ro
m
o
so
m
al
o
rd
er
is
th
e
lo
ca
ti
o
n
o
f
si
gn
ifi
ca
n
t
( S
id
 ak
-c
o
rr
ec
te
d
P
<
0.
05
)D
M
R
s
id
en
ti
fi
ed
in
ea
ch
o
f
th
e
fo
u
r
br
ai
n
re
gi
o
n
s,
w
it
h
th
e
m
ed
ia
n
P-
va
lu
e
fo
r
D
M
R
p
ro
be
s
gi
ve
n
fo
r
th
e
o
th
er
th
re
e
br
ai
n
(b
o
ld
d
en
o
te
s
m
ed
ia
n
P
<
0.
05
an
d
gr
ey
bo
xe
s
d
en
o
te
re
gi
o
n
s
th
at
w
er
e
n
o
t
id
en
ti
fi
ed
in
th
at
br
ai
n
re
gi
o
n
).
T
h
e
‘g
en
e’
co
lu
m
n
li
st
s
th
e
co
m
bi
n
ed
Il
lu
m
in
a
an
d
G
en
o
m
ic
R
eg
io
n
s
En
ri
ch
m
en
t
o
f
A
n
n
o
ta
ti
o
n
T
o
o
l(
G
R
EA
T
)a
n
n
o
ta
ti
o
n
(3
8)
.
R
eg
io
n
G
en
e
Pr
o
be
s
N
p
ro
be
s
Pr
ef
ro
n
ta
lc
o
rt
ex
C
er
eb
el
lu
m
St
ri
at
u
m
H
ip
p
o
ca
m
p
u
s
M
ed
ia
n
P
 Si
d
 ak
P
M
ed
ia
n
P
 Si
d
 ak
P
M
ed
ia
n
P
 Si
d
 ak
P
M
ed
ia
n
P
 Si
d
 ak
P
ch
r1
:8
43
26
54
7-
84
32
68
57
T
T
LL
7
cg
08
88
20
38
;c
g0
78
07
16
5;
cg
02
53
15
16
;
cg
18
11
69
02
;c
g2
63
47
19
7;
cg
24
95
52
04
;
cg
02
48
34
49
7
0.
40
0.
05
0.
03
0.
68
0.
11
ch
r1
:1
68
35
65
37
-1
68
35
66
74
T
BX
19
;X
C
L2
cg
22
69
51
17
;c
g2
06
78
08
2;
cg
10
55
58
00
;
cg
06
12
25
18
4
0.
02
0.
02
0.
13
0.
39
0.
14
ch
r2
:3
48
67
06
-3
48
71
65
A
D
I1
;T
R
A
PP
C
12
cg
14
05
38
28
;c
g1
55
41
04
0;
cg
15
50
68
90
;
cg
08
49
30
51
4
0.
03
2.
82
E-
03
3.
63
E-
04
0.
03
0.
84
ch
r2
:9
74
05
65
1-
97
40
58
80
LM
A
N
2L
cg
13
91
58
92
;c
g0
47
71
93
8;
cg
17
34
09
48
;
cg
17
52
66
58
;c
g1
29
30
81
9;
cg
04
91
83
58
;
cg
15
00
76
26
7
0.
66
5.
73
E-
03
9.
07
E-
03
0.
59
0.
57
ch
r4
:7
48
47
64
6-
74
84
80
17
PF
4
cg
15
15
87
83
;c
g2
10
43
21
3;
cg
16
07
24
62
;
cg
15
39
88
41
;c
g0
25
30
82
4;
cg
06
83
49
98
;
cg
05
50
96
09
;c
g1
31
26
87
1
8
3.
39
E-
03
2.
10
E-
05
0.
16
0.
03
0.
02
ch
r5
:1
02
89
84
63
-1
02
89
87
30
N
U
D
T
12
cg
02
97
66
17
;c
g1
36
65
99
8;
cg
09
16
60
85
;
cg
07
65
56
27
4
2.
27
E-
03
0.
01
0.
08
3.
91
E-
03
0.
31
ch
r5
:4
93
26
2-
49
36
14
SL
C
9A
3;
EX
O
C
3
cg
19
10
75
78
;c
g2
55
18
17
0;
cg
20
40
22
84
;
cg
25
34
69
36
4
0.
76
1.
17
E-
03
3.
87
E-
04
0.
67
0.
72
ch
r5
:4
97
39
7-
49
76
40
cg
22
98
50
16
;c
g1
65
55
55
6;
cg
14
53
37
53
;
cg
00
19
03
55
4
0.
49
5.
41
E-
03
0.
05
0.
17
0.
82
ch
r6
:3
00
42
91
9-
30
04
34
19
R
N
F3
9
cg
12
70
48
54
;c
g1
15
62
28
4;
cg
02
55
23
11
;
cg
03
21
92
82
;c
g2
47
66
42
9;
cg
23
50
07
24
;
cg
10
86
58
56
;c
g2
40
16
62
7;
cg
23
93
98
08
;
cg
12
96
79
14
;c
g0
08
53
04
2;
cg
23
02
75
74
;
cg
05
85
36
32
;c
g2
21
05
33
2;
cg
19
00
64
29
;
cg
27
53
21
87
;c
g0
16
31
16
2
17
0.
06
2.
99
E-
04
0.
40
0.
41
0.
23
ch
r6
:3
30
84
54
9-
33
08
48
41
H
LA
-D
PB
2;
C
O
L1
1A
2
cg
03
94
30
25
;c
g0
86
93
83
2;
cg
27
26
49
93
;
cg
21
87
06
40
;c
g0
80
88
29
5;
cg
17
83
30
71
;
cg
23
07
55
55
;c
g1
35
24
30
2;
cg
02
66
23
62
;
cg
24
46
54
29
;c
g2
42
66
48
5
11
0.
03
0.
04
0.
11
0.
19
0.
23
ch
r1
1:
29
07
67
0-
29
07
75
5
C
D
K
N
1C
cg
05
09
06
95
;c
g1
17
44
76
7;
cg
05
55
94
45
;
cg
23
22
51
47
4
1.
08
E-
03
1.
93
E-
04
0.
08
0.
40
0.
06
ch
r1
2:
75
78
46
17
-7
57
85
09
8
G
LI
PR
1L
2
cg
14
29
26
19
;c
g0
01
08
94
4;
cg
23
58
80
49
;
cg
12
35
11
26
;c
g0
24
15
05
7;
cg
07
31
10
24
;
cg
02
07
12
92
7
0.
66
1.
27
E-
03
2.
49
E-
07
0.
55
0.
19
ch
r1
3:
51
41
78
46
-5
14
18
22
2
D
LE
U
7;
R
N
A
SE
H
2B
;
ST
13
P4
cg
20
17
05
33
;c
g0
82
74
63
7;
cg
13
84
62
70
;
cg
27
05
11
29
;c
g1
03
59
15
7;
cg
20
40
05
92
;
cg
05
96
53
87
;c
g1
72
88
28
8;
cg
03
38
97
01
9
0.
50
8.
88
E-
03
5.
83
E-
04
0.
31
0.
28
ch
r1
3:
11
35
40
40
0-
11
35
40
63
2
A
T
P1
1A
;
M
C
F2
L
cg
17
84
29
18
;c
g1
14
62
09
9;
cg
26
66
62
92
;
cg
11
52
00
03
4
0.
53
0.
17
2.
57
E-
03
0.
01
0.
70
ch
r1
6:
66
40
03
20
-6
64
00
60
0
C
D
H
5
6
0.
68
0.
56
6.
43
E-
03
0.
02
0.
74
(c
o
n
ti
n
u
ed
)
9Human Molecular Genetics, 2016, Vol. 00, No. 00 |
 at U
niversity of Essex on January 12, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
(annotated to TAOK2 on chromosome 16), at which DNA meth-
ylation was positively correlated with PRS (P¼ 4.30E-08)—we
found no significant enrichment of PRS-associated DMPs within
GWAS-nominated schizophrenia-associated regions (Fisher’s
exact test: PFC P¼ 0.83, STR P¼ 0.53, HC P¼ 0.24, CER P¼ 0.53).
We next characterized methylation quantitative trait loci
(mQTLs) associated with the 99,904 variants included in the PRS
calculation, using linkage disequilibrium (LD)-pruned indepen-
dent SNPs and a genome-wide mQTL significance threshold of
P< 3.69E-13, as described in Hannon et al., 2016 (26). Given the
low number of samples from the HC, mQTL analyses were not
performed for this brain region. In total we identified 255 associ-
ations between genetic variants and DNA methylation sites in
the PFC, representing 198 unique SNPs (Supplementary
Material, Table S18), with 247 mQTL pairs (representing 201 in-
dependent SNPs) identified in the STR (Supplementary Material,
Table S19) and 282 mQTL pairs (representing 219 independent
SNPs) identified in the CER (Supplementary Material, Table S20).
None of the top-ranked PRS-associated DMPs in any of the indi-
vidual brain regions, in addition to those identified in the multi-
region model, were significantly associated with any of the ge-
netic variants included in the PRS calculation. Because it is pos-
sible that weaker-effect mQTLs may still underlie some of the
PRS-associated epigenetic variation, we subsequently relaxed
our mQTL significance threshold to P< 1.00E-10, again finding no
overlap with PRS-associated DMPs (Supplementary
Material, Fig. S32). Together, these data indicate that PRS-
associated epigenetic variation does not directly result from ge-
netic influences on DNA methylation in any of the brain regions
tested.
Discussion
In this study, we quantified genome-wide patterns of DNA
methylation in postmortem brain samples isolated from PFC,
STR, HC and CER obtained from two independent cohorts of
schizophrenia patients and controls. We identified numerous
DMPs and DMRs associated with disease and polygenic risk bur-
den; many of these loci were differentially methylated in indi-
vidual brain regions although others showed consistent
patterns across brain regions. Many of the DMPs and DMRs as-
sociated with increased genetic burden for schizophrenia are
independent of the changes observed in the disease itself, and
there is no evidence for direct genetic effects on DNA methyla-
tion (i.e. via mQTLs) for variants included in the PRS. Overall,
our study represents the first analysis of epigenetic variation as-
sociated with schizophrenia across multiple brain regions and
highlights that DNA methylation in the brain is robustly associ-
ated with the polygenic risk burden, independently of many of
the changes observed in the disease itself.
Genes annotated to several of the schizophrenia-associated
DMPs and DMRs have been previously implicated in the patho-
physiology of schizophrenia or have relevant roles in brain
function; such as NCAM1 (which encodes a neural cell adhesion
molecule with a well-established role in neurodevelopment and
synaptic plasticity) (32,33), SYNPO (which encodes a actin-
associated protein that is associated with postsynaptic densi-
ties and dendritic spines and differentially expressed in schizo-
phrenia brain) (34), GBP4 (that encodes a gene that has been
found to be differentially expressed in schizophrenia patients)
(35), PRDM9 (which encodes a protein with histone H3K4 trime-
thyltransferase activity during meiosis that has been previously
hypothesized to play a role in schizophrenia) (36,37) and
WNT5A (an important neurodevelopmental locus) (28). Of note,T
ab
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a DMR spanning four probes within the RPH3AL gene (which en-
codes a protein that plays a direct regulatory role in calcium-
ion-dependent exocytosis), was consistently hypomethylated in
schizophrenia patients across all four brain regions.
Interestingly, this DMR is also functionally annotated to the
DOC2B gene using the Genomic Regions Enrichment of
Annotation Tool (GREAT) (38); this encodes a high-affinity
Ca2þsensor involved in the spontaneous neurotransmitter re-
lease from synaptic vesicles (39). Most notably, the top-ranked
probe associated with PRS in our multi-region model (i.e. across
PFC, STR and HC) is located in the gene body of DISC1, a gene
previously strongly linked to schizophrenia in a Scottish pedi-
gree with a balanced translocation spanning the locus (5). Our
data suggest that an increased PRS for schizophrenia may im-
pact upon regulatory variation of the DISC1 locus in the brain,
implicating a potentially common pathway between polygenic
and highly penetrant single locus aetiologies that warrants fur-
ther investigation.
Despite this being the first study to quantify DNA methyla-
tion across four different brain regions from schizophrenia pa-
tients and controls, this study has a number of important
limitations. First, the number of samples assessed in this study
is relatively low, especially for analyses involving the HC, which
was only available from one of the two brain-bank cohorts.
Despite this, we were able to identify a number of DMPs and
DMRs passing our stringent significance thresholds in both the
analyses of diagnosed schizophrenia and polygenic risk burden.
Furthermore, although the magnitude of change at the differen-
tially methylated loci was relatively small (i.e. involving a rela-
tive small proportion of cells in a given brain region), we were
able to technically validate the Illumina 450K array data using
bisulfite-pyrosequencing. Of note, given the relatively small
number of individual donors, the PRS analyses were undertaken
in both cases and controls, and therefore our study design is po-
tentially confounded in a way that makes it not completely in-
dependent from the schizophrenia analysis. Despite this, we
observed no direct overlap between the top-ranked schizophre-
nia-associated and PRS-associated DMPs although effect sizes
were correlated.
Second, because epigenetic processes play an important role
in defining cell-type-specific patterns of gene expression (40–
42), the use of bulk tissue from each brain region is a potential
confounder in DNA methylation studies (43,44). Despite our ef-
forts to control for the effect of cell type diversity in DNA meth-
ylation quantification in our analyses using in silico approaches,
this approach is not suitable to estimate the neuronal propor-
tion in the cerebellum and cannot inform us about disease rele-
vant DNA methylation changes specific to individual brain cell
types. Third, there is increasing awareness of the importance of
5-hydroxymethyl cytosine (5-hmC) in the human brain (45,46),
although this modification cannot be distinguished from DNA
methylation using standard bisulfite-based approaches (47). It is
therefore plausible that many of the differences identified in
this study are confounded by modifications other than DNA
methylation. To date, no study has evaluated the role of 5-hmC
in schizophrenia or any other psychiatric disorder, although a
recent paper from our group quantified levels of 5-hmC across
the genome in human cortex and cerebellum (47); of note, none
of the significant DMPs identified in this study were character-
ized by detectable levels of this DNA modification.
Definitively distinguishing cause from effect in epigenetic
epidemiology is difficult, especially for disorders like schizo-
phrenia that manifest in inaccessible tissues such as the brain
and are therefore particularly refractory to longitudinal study
Figure 4. Differentially methylated regions (DMRs) associated with schizophrenia polygenic risk score (PRS). Shown in chromosomal order are DMRs (Sidak-corrected
P<0.05, number of probes2) associated with schizophrenia PRS identified in any of the four brain regions. Effect sizes for individual probes within each DMR are also
shown for the other three brain regions (blue¼hypomethylation, red¼hypermethylation). Further details for individual DMRs are provided in Table 5.
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(44). However, our observation of consistent changes across
multiple brain regions in two independent cohorts for many
DMPs and DMRs suggests that the identified loci are potentially
directly relevant to the schizophrenia pathogenesis.
Furthermore, our identification of PRS-associated variation in
DNA methylation potentially less confounded by medication in-
take and other disease-associated exposures that can influence
case-control analyses. We tested if the PRS associations re-
flected the direct effects of genetic variation by testing whether
the genetic variants used to derive the polygenic risk scores are
mQTLs that influence DNA methylation at PRS-associated
DMPs; our analyses suggest that the associations with schizo-
phrenia polygenic burden are independent from genetic varia-
tion itself.
Unlike for GWAS, little work has been done to determine ap-
propriate levels of significance in EWAS and a major issue in the
field of epigenetic epidemiology is that no empirically-derived
thresholds have been established that can be used consistently
across studies (48). To establish a stringent multiple-testing sig-
nificance threshold to identify schizophrenia-associated DMPs,
we utilized data from a large Illumina 450K dataset (n¼ 675 indi-
viduals) generated as a part of recent study from our group (49).
Briefly, we performed 5,000 EWAS permutations using a multi-
ple linear regression model controlling for age, sex, smoking
and cell composition, and used these to estimate the nominal
P-value for 5% family-wise error (P¼ 1.66E-07). Although we be-
lieve this approach to be highly stringent, providing a signifi-
cance threshold that can be used in subsequent EWAS analyses,
it is important to note that the permutations were performed in
an independent dataset.
Although we controlled for age, sex and derived neuronal
composition in our analyses, it is plausible that other factors
may be confounding our case-control analyses of schizophre-
nia, as highlighted by the inflated Q-Q plots observed for several
of the analyses. For example, epidemiological data highlights a
much higher rate of smoking in schizophrenia patients com-
pared to unaffected controls (50,51). Although smoking has
been shown to have striking effects on DNA methylation in
blood (52), none of the robust smoking-associated DMPs identi-
fied in the blood are amongst the schizophrenia DMPs identified
in any of the four brain regions assessed in the current study.
Although P-value inflation is a common feature of many DNA
methylation datasets, standard genomic control methods –
widely used in GWAS – are not suitable for EWAS data (22).
Therefore, we investigated the impact of including additional
surrogate variables capturing variation in DNA methylation on
the association statistics for schizophrenia-associated DMPs
(Supplementary Material, Figs S11–S14), observing that the iden-
tified schizophrenia-associated DMPs are relatively robust to
the major PCs associated with methylomic variance. Of course,
the modest P-value inflation observed in this study does not
necessarily result from residual confounding; it is plausible that
there are multiple differentially methylated loci of small effect
associated with schizophrenia, and that changes across geno-
mic regions are coordinated. Finally, although the control sam-
ples used in this study were selected to be free of psychiatric
morbidity, little additional information about these donors is
available; given the nature of post-mortem tissue, for example,
they will have died from a number of different causes. Although
our study presents novel evidence for associations between
schizophrenia diagnosis, schizophrenia polygenic burden and
variable DNA methylation across different brain regions, further
replication using larger sample sizes is essential to further sup-
port these results. Future studies should focus on
understanding the transcriptional consequences of the ob-
served associations, and testing whether these associations are
causal or a consequence of disease and/or medication.
In summary, our data provide evidence for differences in
DNA methylation across multiple brain regions in schizophre-
nia. We also identify evidence for differential DNA methylation
associated with the increased polygenic burden for schizophre-
nia, including in the vicinity of DISC1, a gene previously impli-
cated in the disease by a highly penetrant balanced
translocation. Of note, there is no enrichment of loci identified
in a recent large GWAS of schizophrenia amongst DMPs for ei-
ther schizophrenia or schizophrenia PRS identified in this study.
Our study represents the first analysis of epigenetic variation
associated with schizophrenia across multiple brain regions
and highlights the utility of polygenic risk scores for identifying
molecular pathways associated with aetiological variation.
Materials and Methods
Post-mortem tissue samples
Post-mortem PFC (Brodmann area 9), STR (putamen), HC, and
CER samples from a total of 41 schizophrenia patients and 47
non-psychiatric control samples were obtained from the MRC
London Neurodegenerative Diseases Brain Bank (LNDBB) (http://
www.kcl.ac.uk/ioppn/depts/bcn/Our-research/Neurodegenera
tion/brain-bank.aspx) and the Douglas-Bell Canada Brain Bank
(DBCBB), Montreal (http://douglasbrainbank.ca/). LNDBB sub-
jects were approached in life for written consent for brain bank-
ing, and all tissue donations were collected and stored
following legal and ethical guidelines (NHS reference number
08/MRE09/38; LBBND brain bank HTA license number 12293).
Schizophrenia patients were diagnosed by trained psychiatrists,
according to the Diagnostic and Statistical Manual of Mental
Disorders criteria. DBCBB samples were collected post-mortem
following consent obtained with next of kin, according to tissue
banking practices regulated by the Quebec Health Research
Fund (http://ethique.msss.gouv.qc.ca/), and based on the OECD
Guidelines on Human Biobanks and Genetic Research
Databases (http://www.oecd.org/science/biotech/44054609.pdf).
Psychiatric diagnoses were based on best-estimate diagnostic
procedures, following SCID I diagnostic interviews conducted
with informants, as described elsewhere (53). The current study
was approved by the University of Exeter Medical School
Research Ethics Committee (reference number 13/02/009). All
samples were dissected by trained neuropathologists from each
brain bank, snap-frozen and stored at 80 C.
Methylomic profiling
Genomic DNA was isolated using a standard phenol-chloroform
extraction protocol and assessed for quality and purity using
spectrophotometry. DNA (500 ng) from each sample was
treated with sodium bisulfite using the EZ-96 Gold DNA methyl-
ation kit (Zymo Research, Irvine, CA, USA). DNA methylation
was quantified using the Illumina Infinium Human
Methylation450 BeadChip (Illumina, San Diego, CA, USA)
scanned on an Illumina HiScan System (Illumina, San Diego,
CA, USA). Samples were batched by tissue and brain-bank, and
randomized with respect to diagnosis, sex and age throughout
all experimental procedures. Illumina Genome Studio software
was used to extract the raw signal intensities of each probe
(without background correction or normalization). QC and nor-
malization steps were performed separately for samples from
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each brain bank. Signal intensities for each probe were im-
ported into R (54) using the methylumi and minfi packages (55,56).
Multidimensional scaling plots of sex chromosome probes were
used to check that the predicted sex corresponded with the re-
ported sex for each individual. The ten bisulfite conversion con-
trol probes on the array were used to calculate the efficiency of
the bisulfite conversion reaction. Comparison of 65 SNP probes
on the array confirmed that matched tissues were sourced from
the same individual. The 65 SNP probes, probes on sex chromo-
somes, cross-hybridizing probes (57,58) and probes containing
an SNP with minor allele frequency> 5% within 10 bp of the sin-
gle base extension position were excluded from analysis (57).
The ‘pfilter’ function of the wateRmelon package (59) was used to
filter data by beadcount and detection P-value. Samples with-
> 1% probes with a detection P-value> 0.01 were removed, along
with probes with a detection P-value> 0.05 in at least 1% of the
samples and/or a beadcount< 3 in 5% of samples were also re-
moved. The ‘dasen’ function in wateRmelon was used to normal-
ize the data as previously described (59). The total number of
CpG sites included and excluded for each brain region in the final
dataset are presented in Supplementary Material, Table S21. In
total 5 PFC, 4 STR, 3 HC and 4 CER samples were excluded during
these stringent QC procedures. The number of samples in the fi-
nal dataset used in the analyses are presented in Table 1.
Genotyping and derivation of schizophrenia polygenic
risk scores
Genomic DNA (200 ng) from each individual was used for geno-
typing on the Illumina Infinium HTS HumanOmniExpress-24
BeadChip v1-0 using an iScan Microarray Scanner (Illumina, San
Diego, CA, USA), according to manufacturer’s instructions.
Illumina GenomeStudio software was used for genotype calling
and the data were exported as .ped and .map files. PLINK (60)
was used to remove samples with> 5% missing data and SNPs
with> 1% missing values, Hardy-Weinberg equilibrium
P< 1.00E-03 or minor allele frequency of< 5%. Sample ethnicity
was determined by merging the genotypes with data from
HapMap Phase 3 (http://www.sanger.ac.uk/resources/downloads/
human/hapmap3.html) and LD pruning the overlapping SNPs
such that no pair of SNPs within 1500 bp had r2>0.20. GCTA soft-
ware (61) was used to calculate principal components of the ge-
netic data, which were visually inspected to ascertain ethnicity
for each sample by comparison with the known ethnicities of the
HapMap sample. Non-Caucasian samples (n¼ 10) were excluded
from PRS analyses. For imputation, genotypes were recoded into
.vcf files using PLINK1.9 (62) and VCFtools (63) before uploading
to the Michigan Imputation Server (https://imputationserver.sph.
umich.edu/start.html#!pages/home), which uses SHAPEIT (64) to
phase haplotypes, and Minimac3 (65) with the most recent 1000
Genomes reference panel (phase 3, version 5) (http://www.
1000genomes.org/). PRSs were calculated in PLINK (60) using the
imputation dosages from 99,940 variants and the score file down-
loaded from the Psychiatric Genomics Consortium (PGC) website
(https://www.med.unc.edu/pgc/downloads) where GWAS results
have been clumped, retaining the best association (identified by
P-value) in each LD block.
Identification of schizophrenia-associated differentially
methylated positions and regions
An overview of the samples included in our schizophrenia case-
control analysis is given in Table 1. We estimated the
proportion of neuronal cells for each sample using the CETS
package in R (43). To identify DMPs in each brain region, we
used linear regression with the preprocessed and normalized
methylation (b) values separately for samples from each brain
bank using disease status, age, sex and neuronal proportion es-
timates as independent variables. Given the nature of the sam-
ples used in this study, information about medication, smoking
status and other phenotypic information was not available and
could not be included as covariates in analyses. Neuronal pro-
portion estimates were not included as a variable for cerebellum
samples because of the high proportion of non-NeuN-
expressing neurons, which make CETS unsuitable for estimat-
ing the cell composition. In our data, cerebellum neuronal esti-
mates derived from CETS correlated significantly with age
(q¼ 0.48, P¼ 1.26E-05) reflecting the previously reported age-
associated variance in the ratio of NeuN-expressing and non-
expressing cells in the cerebellum (43). For tissues collected
from both brain banks (PFC, STR and CER) a fixed-effect meta-
analysis on the adjusted mean b values computed with inverse
variance weights was performed using the ‘metacont’ from the
meta package in R (66). Only probes that survived QC and were
common to both datasets were used in the meta-analysis
(Supplementary Material, Table S21). We employed a fixed-
effects (rather than random-effects) meta-analysis because
with only two sample cohorts contributing to the pooled effect
size, the precision of the estimate of the between-studies vari-
ance is poor using a random-effects model. To identify DMRs,
we identified spatially correlated P-values in our data using the
Python module comb-p (23) to group spatially correlated DMPs
(seed P-value< 1.00E-03, minimum of 2 probes) at a maximum
distance of 300 bp in each brain tissue. DMR P-values were cor-
rected for multiple testing using Sidak correction (67) which cor-
rects the combined P for na/nr tests, where na is the total
number of probes tested in the initial EWAS and nr the number
of probes in the given region. The Bioconductor package
Bumphunter (24) was used to confirm specific DMRs identified by
comb-p with an alternative method. The probes common to the
PFC, STR and HC analyses (411,449 probes) were tested for ho-
mogeneous DNA methylation effects associated with schizo-
phrenia across the three brain regions using a mixed-effects
model with sex, age, neuronal estimates and brain bank as fixed
effects and individual and brain region as random effects.
Identification of polygenic risk score-associated differen-
tially methylated positions and regions
Although the utility of PRS for exploring the molecular genomic
mechanisms involved in disease pathogenesis is largely unex-
plored, PRS-associated epigenetic variation is potentially less af-
fected by factors associated with the disease itself (e.g.
medication exposure, stress and smoking), which can confound
case-control analyses. An overview of the samples included in
our analysis of methylomic variation associated with the poly-
genic burden for schizophrenia is given in Supplementary
Material, Table S1. To identify PRS-associated DMPs we per-
formed a multiple linear regression for each cohort using the
PRS, age, sex and neuronal proportion estimates as independent
variables (except in the CER, where neuronal proportion esti-
mates were not included, as described above). For each of the
tissues collected from both brain banks (PFC, STR and CER), a
fixed-effect meta-analysis based on the linear regression esti-
mates and their standard errors was computed with inverse
variance weights using the ‘metagen’ function from the meta
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package in R (66). Only probes that passed our QC metrics and
were common to both cohorts in each brain region were used in
the meta-analysis (Supplementary Material, Table S21). To iden-
tify PRS-associated DMRs we used comb-p (23) as described
above. To identify homogeneous DNA methylation effects asso-
ciated with PRS across PFC, STR and HC data a mixed effects
model was fitted as described above.
Establishing multiple testing significance threshold for
EWAS analysis
To establish a stringent multiple-testing significance threshold
to identify schizophrenia-associated DMPs, we utilized data
from a large Illumina 450K dataset (n¼ 675 individuals) gener-
ated as part of a recent study from our group (49). The sample
was randomly split into cases and controls 5,000 times, and for
each permutation an EWAS was performed using a multiple lin-
ear regression model controlling for age, sex, smoking and cell
composition, and the probe-level P-values recorded. The mini-
mum or most significant P-value was identified for each permu-
tation and the 5th percentile across the permutations was used
to estimate the nominal P-value for 5% family-wise error
(P¼ 1.66E-07).
Targeted validation using bisulfite-pyrosequencing
Bisulfite-pyrosequencing was used to quantify DNA methyla-
tion across the chr17:154410-154672 region identified in our
DMR analysis. The bisulfite-pyrosequencing assay was designed
using the PyroMark Assay design software (Qiagen, Hilden,
Germany), with bisulfite-PCR amplification performed in dupli-
cate using the primers and assay conditions in Supplementary
Material, Table S22. Fully methylated control samples were in-
cluded in all experiments. DNA methylation was quantified
across amplicons using the Pyromark Q24 system (Qiagen) fol-
lowing the manufacturer’s standard instructions and Pyromark
Q24 CpG 2.0.6 software.
Supplementary Material
Supplementary Material is available at HMG online.
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